Literature DB >> 25487602

Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

P Pedicini1, R Caivano, A Fiorentino, L Strigari.   

Abstract

PURPOSE: To estimate and reduce uncertainties of a self-consistent set of radiobiological parameters based on the outcome of head and neck cancer (HNC) patients treated with radiotherapy (RT).
METHODS: Published studies comparing at least two RT schedules for HNC patients were selected. The method used to estimate the radiobiological parameters consists of three sequential steps that allow a significant reduction of uncertainties: the first, in which the intrinsic (α) and the repair (β) radio-sensitivities were estimated together with the doubling time (T d) by an analytical/graphical method; the second, in which the kick-off time for accelerated proliferation (T k) was estimated applying the hypothesis of activation for sub-populations of stem cells during the RT; the third, in which the number of clonogens (N) was obtained by the Tumor Control Probability (TCP) model. Independent clinical data were used to validate results.
RESULTS: The best estimate and the 95 % confidence intervals (95 % CIs) were: α = 0.24 Gy(-1) (0.23-0.26), β = 0.023 Gy(-2) (0.021-0.025), α/β = 10.6 Gy (8.4-12.6), T d = 3.5 days (3.1-3.9), T k = 19.2 days (15.1-23.3), N = 7 × 10(7) (4 × 10(7)-1 × 10(8)). From these data, the dose required to offset repopulation occurring in 1 day (D prolif) and starting after T k was also estimated as 0.69 Gy/day (0.52-0.86).
CONCLUSIONS: The estimation of all the radiobiological parameters of HNC was obtained based on the hypothesis of activation for specifically tumorigenic sub-populations of stem cells. The similarity of results to those from other studies strengthens such a hypothesis that could be very useful for the predictivity of the TCP model and to design new treatment strategies for HNC.

Entities:  

Mesh:

Year:  2014        PMID: 25487602     DOI: 10.1007/s12094-014-1261-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  In regard to Pedicini et al.

Authors:  Piernicola Pedicini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-12-01       Impact factor: 7.038

2.  Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer.

Authors:  Bernard Cummings; Thomas Keane; Melania Pintilie; Padraig Warde; John Waldron; David Payne; Fei-Fei Liu; Randy Bissett; Michael McLean; Patrick Gullane; Brian O'Sullivan
Journal:  Radiother Oncol       Date:  2007-10       Impact factor: 6.280

3.  Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer.

Authors:  Piernicola Pedicini; Lidia Strigari; Marcello Benassi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-01-17       Impact factor: 7.038

4.  Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).

Authors:  V A Marcial; T F Pajak; C Chang; L Tupchong; J Stetz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-01       Impact factor: 7.038

5.  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.

Authors:  S Dische; M Saunders; A Barrett; A Harvey; D Gibson; M Parmar
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

Review 6.  Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling.

Authors:  J F Fowler
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-02       Impact factor: 4.126

7.  Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Hideaki Katori; Mamoru Tsukuda; Kiichi Watai
Journal:  Cancer Chemother Pharmacol       Date:  2006-11-10       Impact factor: 3.333

8.  Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.

Authors:  P Pedicini; A Fiorentino; G Improta; A Nappi; M Salvatore; G Storto
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

9.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.

Authors:  H K Awwad; M Lotayef; T Shouman; A C Begg; G Wilson; S M Bentzen; H Abd El-Moneim; S Eissa
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  2 in total

1.  The Organ Sparing Potential of Different Biological Optimization Strategies in Proton Therapy.

Authors:  Helge Henjum; Tordis J Dahle; Lars Fredrik Fjæra; Eivind Rørvik; Sara Pilskog; Camilla H Stokkevåg; Andrea Mairani; Kristian S Ytre-Hauge
Journal:  Adv Radiat Oncol       Date:  2021-08-17

2.  Simulation of head and neck cancer oxygenation and doubling time in a 4D cellular model with angiogenesis.

Authors:  Jake C Forster; Michael J J Douglass; Wendy M Harriss-Phillips; Eva Bezak
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.